A study of U.S. men finds that mid-life prostate specific antigen (PSA) levels predict who will be more likely to develop lethal prostate cancer.
Boston, MA—(ENEWSPF)–June 13, 2016. Prostate cancerscreening with prostate-specific antigen (PSA) has been shown to reduce death and the spread of prostate cancer to other parts of the body, but the PSA test remains highly controversial as it frequently leads to over diagnosis and over treatment of men who may not…
